Viral And Non-Viral Vector Manufacturing Market Report 2024 - Market Size, Growth Rate, Major Drivers And Key Trends | Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation

"The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Viral And Non Viral Vector Manufacturing Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The viral and non-viral vector manufacturing market size has grown rapidly in recent years. It will grow from $7.22 billion in 2023 to $8.62 billion in 2024 at a compound annual growth rate (CAGR) of 19.5%. The growth in the historic period can be attributed to rising prevalence of genetic disorders, advancements in biotechnology, increasing investments in gene therapy research, growing awareness of personalized medicine, regulatory support for gene therapy development.

The viral and non-viral vector manufacturing market size is expected to see rapid growth in the next few years. It will grow to $17.85 billion in 2028 at a compound annual growth rate (CAGR) of 20.0%. The growth in the forecast period can be attributed to rising demand for gene therapies, expanding applications in rare diseases treatment, increasing investments in biomanufacturing infrastructure, growing adoption of precision medicine. Major trends in the forecast period include development of next-generation viral vectors, increased use of crispr/cas9 technology in vector manufacturing, focus on scalable and cost-effective manufacturing processes, rising adoption of non-viral vectors, advancements in cell and gene therapy manufacturing technologies.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=12570&type=smp

Market Segmentation:
The viral and non-viral vector manufacturing market covered in this report is segmented -

1) By Vector Type: Viral Vector, Non-Viral Vector
2) By Disease: Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases
3) By Application: Gene Therapy, Vaccinology, Cell Therapy, Other Applications

Major Driver - The Rise Of Vector Therapies In Genetic Disorder Treatment
The increasing prevalence of genetic disorders is expected to propel the growth of the viral and non-viral vector manufacturing markets going forward. Genetic disorders refer to a condition entirely or partially brought on by a deviation from the typical DNA sequence. Viral vectors deliver therapeutic genes to target cells, replacing or supplementing the defective genes that cause genetic disorders. Non-viral vectors are often used in ex vivo gene therapy approaches, where cells are genetically modified outside the body and then reinfused into the patient. For instance, in June 2023, according to Versus Arthritis, a UK-based charity dedicated to supporting people with arthritis, in 2021, around 450,000 people will have rheumatoid arthritis, 190,000 adults will have psoriatic arthritis, and 10 million people will have osteoarthritis, compared to 430,000 people with rheumatoid arthritis, 100,000 adults with psoriatic arthritis, and 8.5 million people with osteoarthritis in 2021, respectively. Furthermore, in June 2022, according to the International Diabetes Federation, a Belgium-based diabetes federation, the prevalence of diabetes had increased to 10.5% worldwide, with over half (44.7%) of people still undiagnosed and around 783 million adults, or one in eight people, expected to have diabetes by 2045. Therefore, the increasing incidence of genetic disorders drives the growth of the viral and non-viral vector manufacturing market.

Competitive Landscape:
Major companies operating in the viral and non-viral vector manufacturing market report are Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/viral-and-non-viral-vector-manufacturing-global-market-report

Top Trend - Merck Kgaa'S Breakthrough In Viral And Non-Viral Solutions
Technological advancements are a key trend gaining popularity in the viral and non-viral vector manufacturing markets. Major companies operating in the viral and non-viral vector manufacturing markets are developing technologically advanced solutions to sustain their position in the market. For instance, in August 2022, Merck KGaA, a Germany-based science and technology company, launched the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. One of the first Contract development and manufacturing organizations and technology creators to offer an entire viral vector manufacturing package, including AAV, Lentiviral, CDMO, CTO, and process development. With the help of this innovative platform, biopharmaceutical businesses may shorten the time and expense of process development while accelerating the time to clinical manufacture.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Viral And Non Viral Vector Manufacturing Market Characteristics
3. Viral And Non Viral Vector Manufacturing Market Trends And Strategies
4. Viral And Non Viral Vector Manufacturing Market - Macro Economic Scenario
5. Viral And Non Viral Vector Manufacturing Market Size And Growth
…..
27. Viral And Non Viral Vector Manufacturing Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.